Global Acne Vulgaris Drug Market

Acne Vulgaris Drug Comprehensive Study by Type (Comedonal, Inflammatory, Cystic, Postsurgical/Wound), Drug Type (OTC Drugs, Prescription Drugs), Drug Class (Retinoids, Antibiotics, Hormonal Agents, Combination Drugs, Others), Route (Topical, Oral, Injectable) Players and Region - Global Market Outlook to 2027

Acne Vulgaris Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Acne Vulgaris Drug
Acne vulgaris is a common chronic skin disease characterized by pilosebaceous unit blockage and/or inflammation hair follicles and their accompanying sebaceous gland. Acne can appear as noninflammatory lesions, inflammatory lesions, or a combination of the two, primarily on the face but also on the back and chest. Acne vulgaris is a common chronic skin disease characterized by pilosebaceous unit blockage and/or inflammation (hair follicles and their accompanying sebaceous gland). Acne can appear as noninflammatory lesions, inflammatory lesions, or a combination of the two, primarily on the face but also on the back and chest.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The competitive landscape has market growth due to the rising prevalence of skin-related diseases such as acne vulgaris. Furthermore, rising public awareness of the benefits of using premium skin care products is propelling market growth. The development of effective therapeutics and treatment alternatives with low side effects and high potential is also driving the market. Another growth-inducing factor is rising consumer preference for products made with natural ingredients. Analyst at AMA Research estimates that United States & United Kingdom Players will contribute the maximum growth to Global Acne Vulgaris Drug market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

ALLERGEN (Ireland), BOTANIX PHARMACEUTICALS (Australia), GALDERMA (Switzerland), GLAXOSMITHKLINE PLC. (United Kingdom), BAYER AG (Germany), ALMIRALL SA (Spain), BAUSCH HEALTH COMPANIES INC. (Canada), GLAXOSMITHKLINE PLC (GSK) (United Kingdom), JOHNSON & JOHNSON (United States) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are MAYNE PHARMA GROUP LIMITED (Australia) and MYLAN N.V. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Acne Vulgaris Drug market by Type (Comedonal, Inflammatory, Cystic and Postsurgical/Wound) and Region.

On the basis of geography, the market of Acne Vulgaris Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. OTC Drugs will boost the Acne Vulgaris Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Retinoids will boost the Acne Vulgaris Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route, the sub-segment i.e. Topical will boost the Acne Vulgaris Drug market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 9th December 2021, Sanofi has agreed to acquire Origimm Biotechnology, a privately held biotechnology company based in Austria that specialises in skin disease, which will add to Sanofi's pipeline of vaccine candidates.
On 25th March 2022, Galderma has announced the US launch of Twyneo (tretinoin 0.1% and benzoyl peroxide 3%) cream for the topical treatment of acne vulgaris in patients 9 years of age and older. Twyneo is a fixed-dose combination of tretinoin 0.1%, a retinoid, and benzoyl peroxide 3%, a topical antibacterial. The formulation of Twyneo uses silica core shell structures to separately microencapsulate tretinoin crystals and benzoyl peroxide crystals enabling inclusion of the 2 active ingredients in the cream.


Market Drivers
  • Increasing Prevalence and Severity of Acne Vulgaris Drug
  • Rise in Concern for Facial Aesthetics

Opportunities
  • Increase in Prevalence of Acne Vulgaris Drug Condition in Teenagers and Adults
  • Research and Development Activity Related to New Therapeutics with Lesser Side Effects

Restraints
  • Stringent Government Rules and Regulation for Acne Vulgaris Drugs

Challenges
  • Stringent Government Rules and Regulation for Acne Vulgaris Drugs


Key Target Audience
New Entrants and Investors, Analysts and Strategic Business Planners, Acne Vulgaris Drug Manufacturer, Acne Vulgaris Drug Distributors and Suppliers, Acne Vulgaris Drug Providers, Venture Capitalists and Private Equity Firms, Government Bodies, End-Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Comedonal
  • Inflammatory
  • Cystic
  • Postsurgical/Wound
By Drug Type
  • OTC Drugs
  • Prescription Drugs

By Drug Class
  • Retinoids
  • Antibiotics
  • Hormonal Agents
  • Combination Drugs
  • Others

By Route
  • Topical
  • Oral
  • Injectable

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence and Severity of Acne Vulgaris Drug
      • 3.2.2. Rise in Concern for Facial Aesthetics
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulation for Acne Vulgaris Drugs
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption of Skin Care Products through E-commerce
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acne Vulgaris Drug, by Type, Drug Type, Drug Class, Route and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Acne Vulgaris Drug (Value)
      • 5.2.1. Global Acne Vulgaris Drug by: Type (Value)
        • 5.2.1.1. Comedonal
        • 5.2.1.2. Inflammatory
        • 5.2.1.3. Cystic
        • 5.2.1.4. Postsurgical/Wound
      • 5.2.2. Global Acne Vulgaris Drug by: Drug Type (Value)
        • 5.2.2.1. OTC Drugs
        • 5.2.2.2. Prescription Drugs
      • 5.2.3. Global Acne Vulgaris Drug by: Drug Class (Value)
        • 5.2.3.1. Retinoids
        • 5.2.3.2. Antibiotics
        • 5.2.3.3. Hormonal Agents
        • 5.2.3.4. Combination Drugs
        • 5.2.3.5. Others
      • 5.2.4. Global Acne Vulgaris Drug by: Route (Value)
        • 5.2.4.1. Topical
        • 5.2.4.2. Oral
        • 5.2.4.3. Injectable
      • 5.2.5. Global Acne Vulgaris Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Acne Vulgaris Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ALLERGEN (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BOTANIX PHARMACEUTICALS (Australia)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GALDERMA (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GLAXOSMITHKLINE PLC. (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BAYER AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. ALMIRALL SA (Spain)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BAUSCH HEALTH COMPANIES INC. (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GLAXOSMITHKLINE PLC (GSK) (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. JOHNSON & JOHNSON (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. SUN PHARMACEUTICAL INDUSTRIES LIMITED (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Acne Vulgaris Drug Sale, by Type, Drug Type, Drug Class, Route and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Acne Vulgaris Drug (Value)
      • 7.2.1. Global Acne Vulgaris Drug by: Type (Value)
        • 7.2.1.1. Comedonal
        • 7.2.1.2. Inflammatory
        • 7.2.1.3. Cystic
        • 7.2.1.4. Postsurgical/Wound
      • 7.2.2. Global Acne Vulgaris Drug by: Drug Type (Value)
        • 7.2.2.1. OTC Drugs
        • 7.2.2.2. Prescription Drugs
      • 7.2.3. Global Acne Vulgaris Drug by: Drug Class (Value)
        • 7.2.3.1. Retinoids
        • 7.2.3.2. Antibiotics
        • 7.2.3.3. Hormonal Agents
        • 7.2.3.4. Combination Drugs
        • 7.2.3.5. Others
      • 7.2.4. Global Acne Vulgaris Drug by: Route (Value)
        • 7.2.4.1. Topical
        • 7.2.4.2. Oral
        • 7.2.4.3. Injectable
      • 7.2.5. Global Acne Vulgaris Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acne Vulgaris Drug: by Type(USD Million)
  • Table 2. Acne Vulgaris Drug Comedonal , by Region USD Million (2016-2021)
  • Table 3. Acne Vulgaris Drug Inflammatory , by Region USD Million (2016-2021)
  • Table 4. Acne Vulgaris Drug Cystic , by Region USD Million (2016-2021)
  • Table 5. Acne Vulgaris Drug Postsurgical/Wound , by Region USD Million (2016-2021)
  • Table 6. Acne Vulgaris Drug: by Drug Type(USD Million)
  • Table 7. Acne Vulgaris Drug OTC Drugs , by Region USD Million (2016-2021)
  • Table 8. Acne Vulgaris Drug Prescription Drugs , by Region USD Million (2016-2021)
  • Table 9. Acne Vulgaris Drug: by Drug Class(USD Million)
  • Table 10. Acne Vulgaris Drug Retinoids , by Region USD Million (2016-2021)
  • Table 11. Acne Vulgaris Drug Antibiotics , by Region USD Million (2016-2021)
  • Table 12. Acne Vulgaris Drug Hormonal Agents , by Region USD Million (2016-2021)
  • Table 13. Acne Vulgaris Drug Combination Drugs , by Region USD Million (2016-2021)
  • Table 14. Acne Vulgaris Drug Others , by Region USD Million (2016-2021)
  • Table 15. Acne Vulgaris Drug: by Route(USD Million)
  • Table 16. Acne Vulgaris Drug Topical , by Region USD Million (2016-2021)
  • Table 17. Acne Vulgaris Drug Oral , by Region USD Million (2016-2021)
  • Table 18. Acne Vulgaris Drug Injectable , by Region USD Million (2016-2021)
  • Table 19. South America Acne Vulgaris Drug, by Country USD Million (2016-2021)
  • Table 20. South America Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 21. South America Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 22. South America Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 23. South America Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 24. Brazil Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 25. Brazil Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 26. Brazil Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 27. Brazil Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 28. Argentina Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 29. Argentina Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 30. Argentina Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 31. Argentina Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 32. Rest of South America Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 33. Rest of South America Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 34. Rest of South America Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 35. Rest of South America Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 36. Asia Pacific Acne Vulgaris Drug, by Country USD Million (2016-2021)
  • Table 37. Asia Pacific Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 38. Asia Pacific Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 39. Asia Pacific Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 40. Asia Pacific Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 41. China Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 42. China Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 43. China Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 44. China Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 45. Japan Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 46. Japan Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 47. Japan Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 48. Japan Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 49. India Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 50. India Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 51. India Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 52. India Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 53. South Korea Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 54. South Korea Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 55. South Korea Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 56. South Korea Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 57. Australia Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 58. Australia Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 59. Australia Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 60. Australia Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 61. Rest of Asia-Pacific Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 65. Europe Acne Vulgaris Drug, by Country USD Million (2016-2021)
  • Table 66. Europe Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 67. Europe Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 68. Europe Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 69. Europe Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 70. Germany Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 71. Germany Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 72. Germany Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 73. Germany Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 74. France Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 75. France Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 76. France Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 77. France Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 78. Italy Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 79. Italy Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 80. Italy Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 81. Italy Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 82. United Kingdom Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 83. United Kingdom Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 84. United Kingdom Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 85. United Kingdom Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 86. Netherlands Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 87. Netherlands Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 88. Netherlands Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 89. Netherlands Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 90. Rest of Europe Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 91. Rest of Europe Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 92. Rest of Europe Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 93. Rest of Europe Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 94. MEA Acne Vulgaris Drug, by Country USD Million (2016-2021)
  • Table 95. MEA Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 96. MEA Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 97. MEA Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 98. MEA Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 99. Middle East Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 100. Middle East Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 101. Middle East Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 102. Middle East Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 103. Africa Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 104. Africa Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 105. Africa Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 106. Africa Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 107. North America Acne Vulgaris Drug, by Country USD Million (2016-2021)
  • Table 108. North America Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 109. North America Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 110. North America Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 111. North America Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 112. United States Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 113. United States Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 114. United States Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 115. United States Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 116. Canada Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 117. Canada Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 118. Canada Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 119. Canada Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 120. Mexico Acne Vulgaris Drug, by Type USD Million (2016-2021)
  • Table 121. Mexico Acne Vulgaris Drug, by Drug Type USD Million (2016-2021)
  • Table 122. Mexico Acne Vulgaris Drug, by Drug Class USD Million (2016-2021)
  • Table 123. Mexico Acne Vulgaris Drug, by Route USD Million (2016-2021)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Acne Vulgaris Drug: by Type(USD Million)
  • Table 135. Acne Vulgaris Drug Comedonal , by Region USD Million (2022-2027)
  • Table 136. Acne Vulgaris Drug Inflammatory , by Region USD Million (2022-2027)
  • Table 137. Acne Vulgaris Drug Cystic , by Region USD Million (2022-2027)
  • Table 138. Acne Vulgaris Drug Postsurgical/Wound , by Region USD Million (2022-2027)
  • Table 139. Acne Vulgaris Drug: by Drug Type(USD Million)
  • Table 140. Acne Vulgaris Drug OTC Drugs , by Region USD Million (2022-2027)
  • Table 141. Acne Vulgaris Drug Prescription Drugs , by Region USD Million (2022-2027)
  • Table 142. Acne Vulgaris Drug: by Drug Class(USD Million)
  • Table 143. Acne Vulgaris Drug Retinoids , by Region USD Million (2022-2027)
  • Table 144. Acne Vulgaris Drug Antibiotics , by Region USD Million (2022-2027)
  • Table 145. Acne Vulgaris Drug Hormonal Agents , by Region USD Million (2022-2027)
  • Table 146. Acne Vulgaris Drug Combination Drugs , by Region USD Million (2022-2027)
  • Table 147. Acne Vulgaris Drug Others , by Region USD Million (2022-2027)
  • Table 148. Acne Vulgaris Drug: by Route(USD Million)
  • Table 149. Acne Vulgaris Drug Topical , by Region USD Million (2022-2027)
  • Table 150. Acne Vulgaris Drug Oral , by Region USD Million (2022-2027)
  • Table 151. Acne Vulgaris Drug Injectable , by Region USD Million (2022-2027)
  • Table 152. South America Acne Vulgaris Drug, by Country USD Million (2022-2027)
  • Table 153. South America Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 154. South America Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 155. South America Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 156. South America Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 157. Brazil Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 158. Brazil Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 159. Brazil Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 160. Brazil Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 161. Argentina Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 162. Argentina Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 163. Argentina Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 164. Argentina Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 165. Rest of South America Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 166. Rest of South America Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 167. Rest of South America Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 168. Rest of South America Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 169. Asia Pacific Acne Vulgaris Drug, by Country USD Million (2022-2027)
  • Table 170. Asia Pacific Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 171. Asia Pacific Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 172. Asia Pacific Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 173. Asia Pacific Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 174. China Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 175. China Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 176. China Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 177. China Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 178. Japan Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 179. Japan Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 180. Japan Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 181. Japan Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 182. India Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 183. India Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 184. India Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 185. India Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 186. South Korea Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 187. South Korea Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 188. South Korea Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 189. South Korea Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 190. Australia Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 191. Australia Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 192. Australia Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 193. Australia Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 194. Rest of Asia-Pacific Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 195. Rest of Asia-Pacific Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 196. Rest of Asia-Pacific Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 198. Europe Acne Vulgaris Drug, by Country USD Million (2022-2027)
  • Table 199. Europe Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 200. Europe Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 201. Europe Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 202. Europe Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 203. Germany Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 204. Germany Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 205. Germany Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 206. Germany Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 207. France Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 208. France Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 209. France Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 210. France Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 211. Italy Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 212. Italy Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 213. Italy Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 214. Italy Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 215. United Kingdom Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 216. United Kingdom Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 217. United Kingdom Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 218. United Kingdom Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 219. Netherlands Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 220. Netherlands Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 221. Netherlands Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 222. Netherlands Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 223. Rest of Europe Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 224. Rest of Europe Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 225. Rest of Europe Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 226. Rest of Europe Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 227. MEA Acne Vulgaris Drug, by Country USD Million (2022-2027)
  • Table 228. MEA Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 229. MEA Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 230. MEA Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 231. MEA Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 232. Middle East Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 233. Middle East Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 234. Middle East Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 235. Middle East Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 236. Africa Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 237. Africa Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 238. Africa Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 239. Africa Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 240. North America Acne Vulgaris Drug, by Country USD Million (2022-2027)
  • Table 241. North America Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 242. North America Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 243. North America Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 244. North America Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 245. United States Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 246. United States Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 247. United States Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 248. United States Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 249. Canada Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 250. Canada Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 251. Canada Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 252. Canada Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 253. Mexico Acne Vulgaris Drug, by Type USD Million (2022-2027)
  • Table 254. Mexico Acne Vulgaris Drug, by Drug Type USD Million (2022-2027)
  • Table 255. Mexico Acne Vulgaris Drug, by Drug Class USD Million (2022-2027)
  • Table 256. Mexico Acne Vulgaris Drug, by Route USD Million (2022-2027)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acne Vulgaris Drug: by Type USD Million (2016-2021)
  • Figure 5. Global Acne Vulgaris Drug: by Drug Type USD Million (2016-2021)
  • Figure 6. Global Acne Vulgaris Drug: by Drug Class USD Million (2016-2021)
  • Figure 7. Global Acne Vulgaris Drug: by Route USD Million (2016-2021)
  • Figure 8. South America Acne Vulgaris Drug Share (%), by Country
  • Figure 9. Asia Pacific Acne Vulgaris Drug Share (%), by Country
  • Figure 10. Europe Acne Vulgaris Drug Share (%), by Country
  • Figure 11. MEA Acne Vulgaris Drug Share (%), by Country
  • Figure 12. North America Acne Vulgaris Drug Share (%), by Country
  • Figure 13. Global Acne Vulgaris Drug share by Players 2021 (%)
  • Figure 14. Global Acne Vulgaris Drug share by Players (Top 3) 2021(%)
  • Figure 15. Global Acne Vulgaris Drug share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. ALLERGEN (Ireland) Revenue, Net Income and Gross profit
  • Figure 18. ALLERGEN (Ireland) Revenue: by Geography 2021
  • Figure 19. BOTANIX PHARMACEUTICALS (Australia) Revenue, Net Income and Gross profit
  • Figure 20. BOTANIX PHARMACEUTICALS (Australia) Revenue: by Geography 2021
  • Figure 21. GALDERMA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. GALDERMA (Switzerland) Revenue: by Geography 2021
  • Figure 23. GLAXOSMITHKLINE PLC. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. GLAXOSMITHKLINE PLC. (United Kingdom) Revenue: by Geography 2021
  • Figure 25. BAYER AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. BAYER AG (Germany) Revenue: by Geography 2021
  • Figure 27. ALMIRALL SA (Spain) Revenue, Net Income and Gross profit
  • Figure 28. ALMIRALL SA (Spain) Revenue: by Geography 2021
  • Figure 29. BAUSCH HEALTH COMPANIES INC. (Canada) Revenue, Net Income and Gross profit
  • Figure 30. BAUSCH HEALTH COMPANIES INC. (Canada) Revenue: by Geography 2021
  • Figure 31. GLAXOSMITHKLINE PLC (GSK) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GLAXOSMITHKLINE PLC (GSK) (United Kingdom) Revenue: by Geography 2021
  • Figure 33. JOHNSON & JOHNSON (United States) Revenue, Net Income and Gross profit
  • Figure 34. JOHNSON & JOHNSON (United States) Revenue: by Geography 2021
  • Figure 35. SUN PHARMACEUTICAL INDUSTRIES LIMITED (India) Revenue, Net Income and Gross profit
  • Figure 36. SUN PHARMACEUTICAL INDUSTRIES LIMITED (India) Revenue: by Geography 2021
  • Figure 37. Global Acne Vulgaris Drug: by Type USD Million (2022-2027)
  • Figure 38. Global Acne Vulgaris Drug: by Drug Type USD Million (2022-2027)
  • Figure 39. Global Acne Vulgaris Drug: by Drug Class USD Million (2022-2027)
  • Figure 40. Global Acne Vulgaris Drug: by Route USD Million (2022-2027)
  • Figure 41. South America Acne Vulgaris Drug Share (%), by Country
  • Figure 42. Asia Pacific Acne Vulgaris Drug Share (%), by Country
  • Figure 43. Europe Acne Vulgaris Drug Share (%), by Country
  • Figure 44. MEA Acne Vulgaris Drug Share (%), by Country
  • Figure 45. North America Acne Vulgaris Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ALLERGEN (Ireland)
  • BOTANIX PHARMACEUTICALS (Australia)
  • GALDERMA (Switzerland)
  • GLAXOSMITHKLINE PLC. (United Kingdom)
  • BAYER AG (Germany)
  • ALMIRALL SA (Spain)
  • BAUSCH HEALTH COMPANIES INC. (Canada)
  • GLAXOSMITHKLINE PLC (GSK) (United Kingdom)
  • JOHNSON & JOHNSON (United States)
  • SUN PHARMACEUTICAL INDUSTRIES LIMITED (India)
Additional players considered in the study are as follows:
MAYNE PHARMA GROUP LIMITED (Australia) , MYLAN N.V. (United States) ,
Select User Access Type

Key Highlights of Report


Jun 2022 212 Pages 58 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Acne Vulgaris Drug Market Quantitative research analysis
Global Acne Vulgaris Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as ALLERGEN (Ireland), BOTANIX PHARMACEUTICALS (Australia), GALDERMA (Switzerland), GLAXOSMITHKLINE PLC. (United Kingdom), BAYER AG (Germany), ALMIRALL SA (Spain), BAUSCH HEALTH COMPANIES INC. (Canada), GLAXOSMITHKLINE PLC (GSK) (United Kingdom), JOHNSON & JOHNSON (United States) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Adoption of Skin Care Products through E-commerce" is seen as one of major influencing trends for Acne Vulgaris Drug Market during projected period 2021-2027.

Know More About Global Acne Vulgaris Drug Market Report?

Have a Query? Click Here

Other Related Reports

Cardiac Medication Comprehensive Study by Type (Anticoagulants, Antiplatelet medications, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin receptor blockers (ARBs)), Application (Hospitals...
$ 3800
Multi-Dose Medication Comprehensive Study by End-users (Hospitals & Clinics, Pharmacies, Others), Software (Computerized Physician Order Entry, Clinical Decision Support System, Automated Dispensing ...
$ 3500
Pet Deworming Comprehensive Study by Application (Pain Relief & Arthritis, Allergy Relief, Antibiotics, Fleas & Ticks), Types of worms (Hookworms, Roundworms, Tapeworms, Whipworms), Distribution Chan...
$ 4000
Online Drug Retail Chain Comprehensive Study by Type (Skin Care, Dental, Weight Loss, Others), Drug (Prescription Drugs, Non-prescription Drugs), Platform (Web-Based, App-Based) Players and Region - ...
$ 3500
SGOT Test Comprehensive Study by Type (Instruments, Kits and Reagents), Application (Hospitals, Specialty Clinics, Ambulatory Surgical Centre) Players and Region - Global Market Outlook to 2027
$ 3500
Narcotic Drugs Comprehensive Study by Type (Opium, Heroin, Demerol, Darvon, Others), Types (Stimulants (E.G. Cocaine), Depressants (E.G. Alcohol), Opium-Related Painkillers (E.G. Heroin), Hallucinoge...
$ 4000